Abstract
Eye is a vital sense organ of our body and any disorder can lead to serious medical implications that may put great financial burden on patient and their family. Effective drug delivery to the eye is a challenging proposition for the pharmaceutical scientist. Eye drops have been globally accepted as a formulation for anterior segment applications. On one hand it is widely used owing to its convenience but is also associated with some limitations in terms of desired pharmacological and pharmacokinetic profile, dosing frequency, systemic untoward effects, patient noncompliance, low drug bioavailability due to transient contact time, rapid washout by tearing and nasolacrimal drainage. The need to overcome these major issues related to ocular pharmacotherapy has been long recognized. Several novel nanocarriers including nanolipid based carrier systems have been widely explored and investigated for ophthalmic applications. These include solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, in situ gels, niosomes, mucoadhesive systems and discomes. Since lipids have similar structure to human cell lipids, their biodegradable, non-toxic and biocompatible profile are particularly useful. Additionally, they also offer protection against drug degradation, impart controlled drug release characteristics and site specific delivery. This review explores the potential feasibility of lipid component in formulation of nanomedicine for ophthalmic delivery and reports the clinical findings in order to improve the ocular pharmacotherapy. Here, we also discussed for patents related to the topic.
Keywords: Biodegradation, eye, lipid nanocarrier, ophthalmic delivery, patents.
Graphical Abstract
Recent Patents on Nanotechnology
Title:Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers
Volume: 9 Issue: 2
Author(s): Abhishek K. Sah and Preeti K. Suresh
Affiliation:
Keywords: Biodegradation, eye, lipid nanocarrier, ophthalmic delivery, patents.
Abstract: Eye is a vital sense organ of our body and any disorder can lead to serious medical implications that may put great financial burden on patient and their family. Effective drug delivery to the eye is a challenging proposition for the pharmaceutical scientist. Eye drops have been globally accepted as a formulation for anterior segment applications. On one hand it is widely used owing to its convenience but is also associated with some limitations in terms of desired pharmacological and pharmacokinetic profile, dosing frequency, systemic untoward effects, patient noncompliance, low drug bioavailability due to transient contact time, rapid washout by tearing and nasolacrimal drainage. The need to overcome these major issues related to ocular pharmacotherapy has been long recognized. Several novel nanocarriers including nanolipid based carrier systems have been widely explored and investigated for ophthalmic applications. These include solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), liposomes, in situ gels, niosomes, mucoadhesive systems and discomes. Since lipids have similar structure to human cell lipids, their biodegradable, non-toxic and biocompatible profile are particularly useful. Additionally, they also offer protection against drug degradation, impart controlled drug release characteristics and site specific delivery. This review explores the potential feasibility of lipid component in formulation of nanomedicine for ophthalmic delivery and reports the clinical findings in order to improve the ocular pharmacotherapy. Here, we also discussed for patents related to the topic.
Export Options
About this article
Cite this article as:
K. Sah Abhishek and K. Suresh Preeti, Recent Advances in Ocular Drug Delivery, with Special Emphasis on Lipid Based Nanocarriers, Recent Patents on Nanotechnology 2015; 9 (2) . https://dx.doi.org/10.2174/187221050902150819151841
DOI https://dx.doi.org/10.2174/187221050902150819151841 |
Print ISSN 1872-2105 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4020 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Medicinal Chemistry Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Glucocorticoid-Induced Hypertension and Tetrahydrobiopterin (BH4), a Common Cofactor for the Production of Vasoactive Molecules
Current Hypertension Reviews VEGF, BMP-7, Matrigel<sup>TM</sup>, Hyaluronic Acid, In Vitro Cultured Chondrocytes and Trephination for Healing of the Avascular Portion of the Meniscus. An Experimental Study in Sheep
Current Stem Cell Research & Therapy Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies CD14 and Toll-Like Receptors: Potential Contribution of Genetic Factors and Mechanisms to Inflammation and Allergy
Current Drug Targets - Inflammation & Allergy The Role of Epithelial-Mesenchymal Interactions in Tissue Repair, Fibrogenesis and Carcinogenesis
Current Signal Transduction Therapy ACKNOWLEDGEMENTS TO CONTRIBUTORS
Recent Patents on Inflammation & Allergy Drug Discovery Behcets Syndrome: Literature Review
Current Rheumatology Reviews Non-Analgesic Effects of Opioids: Mechanisms and Potential Clinical Relevance of Opioid-Induced Immunodepression
Current Pharmaceutical Design Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design Assessments of Immunomodulatory and Inflammatory effects against Induction of Entamoeba histolytica (HM1 IMS strain) crude extract Antigen in Complete Freund’s Adjuvant Induced Rheumatoid Arthritis Female Wistar Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: The Administration of Non-Steroidal Anti-Inflammatory Drugs and Selective Cyclooxygenase-2 Inhibitors in Dentistry (Executive Editor: Saynur Vardar)]
Current Pharmaceutical Design Human Fetal Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry
Current Medicinal Chemistry Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing- Remitting Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets